Glenmark Pharma targets zero gross debt by March 2026
after close1 source ↓written by the desknot a recommendation
- capital expenditure plan
- ₹800 cr
- by the deadline
- 115 days
Glenmark Pharmaceuticals aims to achieve zero gross debt by March 2026, supported by a ₹800 cr capital expenditure plan. The company is focused on optimizing its net working capital cycle, currently at about 110 days, while targeting 115 days by the deadline. This strategic move is expected to enhance operational efficiency and financial stability.
Not investment advice. For informational purposes only.